Information  X 
Enter a valid email address

UCB (0GD8)

  Print      Mail a friend       Annual reports

Thursday 30 April, 2009

UCB

UCB focuses on new product launches





  * Earnings performance in-line with company expectations but
    revenue declines
  * New product launches on track
  * SHAPE programme continues to focus on core priorities and
    streamlining the organisation
  * Cimzia® response letter on rheumatoid arthritis submitted to U.S.
    FDA
  * Outlook 2009: revenue between EUR 3.1-3.3 billion, recurring
    EBITDA greater than EUR 680 million, net profit to exceed EUR 130
    million

Brussels (Belgium), April 30, 2009 - 7:00 AM (CET) - press release,
regulated information - UCB announced today its interim report for
the first quarter of 2009.

"In the first three months of 2009, UCB has made further progress in
focusing its resources and organisation on its core priorities in
severe diseases of the central nervous system and immunology. We are
preparing to launch Vimpat® in adjunctive therapy for epilepsy in the
U.S. and in additional European countries, Cimzia® in rheumatoid
arthritis in the U.S. and in Europe, and Neupro® in Parkinson's
disease and restless legs syndrome in Europe", said Roch Doliveux,
CEO of UCB.

In the period from January to March 2009, UCB's revenue decreased
compared to the first three months in 2008 due to a lower net sales
contribution from the U.S. market. Recurring EBITDA and net profit
performance were in line with the company's expectation.

In the U.S. market, net sales of the Keppra® (levetiracetam)
franchise decreased following loss of exclusivity. Net sales of the
anti-tussive, Tussionex® (hydrocodone polistirex and chlorpheniramine
polistirex), decreased compared to the same period last year due to a
weak cough and cold season. The attention deficit and hyperactivity
disorder product, Metadate(TM) CD (methylphenidate), however,
continued to grow strongly in the U.S. market.

Key products in Europe and in the rest of the world outside the U.S.
were Keppra® which continued to show strong sales growth and the
allergy product, Zyrtec® (cetirizine), in Japan which is growing
strongly because of a more severe pollen season.

New product launches
Cimzia® (certolizumab pegol) roll-out in the U.S. for the treatment
of Crohn's disease continues with over 6 200 patients being
prescribed the product since launch in April 2008.

Keppra® XR, an extended release formulation of levetiracetam, was
launched at the end of September 2008 in the U.S. and continues to
gain market share at a rate above the original launch of Keppra® in
the U.S.

The European market introduction of Vimpat® (lacosamide) is ongoing
with more than 5 000 patients already benefiting from the drug and
the launch outperforming the two most recent anti-epileptic drug
launches. Vimpat® is now launched in Germany, UK, Austria, Greece,
Denmark, Sweden, Netherlands, and more European countries will
follow.

SHAPE
UCB continued to focus its organisation and resources on its core
products and geographies, in particular on its products and
development projects for severe diseases in the central nervous
system (CNS) and immunology. In the first quarter of 2009, UCB
concluded a transaction with GlaxoSmithKline for the divestiture of
selected smaller emerging markets. UCB also divested Equasym(TM)
IR/XL (methylphenidate)to Shire and Somatostatine-UCB® to Eumedica.
All these transactions have now closed and UCB will publish further
financial details in its half-year 2009 report, due 31st July, 2009.

At the end of March 2009, UCB had achieved more than 80% of its
original 17% (or 2 000 positions) worldwide work force reduction
target set in August 2008.

Development pipeline update
Following the receipt of a Complete Response Letter in January 2009,
UCB recently submitted the additional safety update on Cimzia® in
rheumatoid arthritis requested by the Food and Drug Administration
(FDA).

UCB expects to make Vimpat® available in the U.S. during the second
quarter of 2009. In October 2008, the FDA approved Vimpat® as
adjunctive therapy for adults with partial-onset seizures and also
proposed that Vimpat® be designated as a Schedule V drug. As a
result, Vimpat® is undergoing the normal process to confirm drug
scheduling with the U.S. Drug Enforcement Agency (DEA). U.S. drug
schedules range from Schedule I to Schedule V with Schedule V drugs
considered to have the lowest potential for abuse.

UCB is working with the regulatory authorities to make Neupro®
(rotigotine) available again to patients suffering from Parkinson's
disease (including new patients) in Europe, and to launch the
restless legs syndrome indication in Europe, during the second
quarter of 2009. A complete cold-chain storage and distribution
system which minimises the development of crystals on Neupro®
patches was successfully implemented in Europe in September 2008.  A
dialogue with the FDA to resolve the U.S. out-of-stock situation of
Neupro® is ongoing.

Toviaz® (fesoterodine fumarate) was launched by Pfizer in the U.S. in
the first week of April for the treatment of overactive bladder,
following approval in the U.S. in October 2008. In Europe, Toviaz® is
also approved and was launched by Pfizer mid-2008. UCB is entitled to
receive royalties on the combined sales of Toviaz® and Pfizer's
tolterodine product franchise.

Earlier this week, UCB announced first results from Phase III
brivaracetam studies in epilepsy. One study met its primary efficacy
endpoint while the second study did not meet its primary efficacy
endpoint. A third safety and tolerability study confirmed
brivaracetam was well tolerated. Further analysis will be conducted
and regulatory authorities will be consulted to determine next steps
to bring brivaracetam to patients. During the third quarter of 2009,
UCB expects to see first Phase IIb results for epratuzumab in
systemic lupus erythematosus (SLE).

Financial outlook 2009
Taking into consideration the trends seen in the first quarter of
2009, full year revenue is expected to reach between EUR 3.1-3.3
billion.

Recurring EBITDA is expected to end the year greater than EUR 680
million.

Net profit, as reported, is expected to exceed EUR 130 million for
the full year 2009, excluding the capital gains resulting from the
already-announced divestitures concluded in the first quarter of
2009.


For further information
Antje Witte, Corporate Communications & Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com

Richard Simpson, Investor Relations, UCB
T+32.2.559.9494, richard.simpson@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, michael.tuck-sherman@ucb.com

Nancy Nackaerts, External Communications, UCB
T +32 2 559 9264, nancy.nackaerts@ucb.com


About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company
dedicated to the research, development and commercialisation of
innovative medicines with a focus on the fields of the central
nervous system and immunology disorders. Employing approximately 10
000 people in over 40 countries, UCB generated revenue of EUR 3.6
billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.

For the pdf-version of this press release, please click on the link
below:


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.